Jeff, no one has mentioned the data on 18,000 patients. But I believe that Abbvie and Dr Snabes have the 5 years of data on 3656 patients to support the new claims. It would be consistent with the followup obligation to the patients as per FDA SPA.
I also think Abbvie is sensing an urgency to get Libigel moving. Especially if the UK High Court trial that start today goes against Abbvie. It could hit PPS hard and they need something to counter with and stabilize PPS.
It looks like Abbvie claiming they have a strong defensible patent portfolio to defend Humira is going to have to put all their card on the table. If they lose Humira Biosimilars hit the shelves in the EU in 2018.